Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Stemcell United Ltd. ( (AU:BP8) ).
BPH Global has reported its December quarter activities, highlighting completion of the second tranche of a capital raising of up to A$1.1 million through the issue of 550 million shares with attached options, following shareholder approval in November, and ending the period with cash of around A$0.598 million. Operationally, the group continued to consolidate and scale its Indonesian seaweed trading business, delivering record monthly sales in October–November, a rebound to near-record volumes in the subsequent month, strengthening customer relationships and sourcing capacity via its Makassar warehouse, and securing a key Indonesian seaweed export licence that enables direct international sales, underpinning a positive outlook for 2026.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
More about Stemcell United Ltd.
BPH Global Limited is an ASX-listed plant-based biotechnology company focused on the growth and commercialisation of Indonesia-based seaweed operations. The company is building an integrated sourcing, processing, trading and export platform, leveraging its Makassar warehouse and sales channels to serve both domestic and international markets.
Current Market Cap: A$1.85M
Find detailed analytics on BP8 stock on TipRanks’ Stock Analysis page.